{"id":342715,"date":"2026-11-10T10:11:25","date_gmt":"2026-11-10T04:41:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=342715"},"modified":"2026-11-10T10:11:25","modified_gmt":"2026-11-10T04:41:25","slug":"bliss-gvs-pharma-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/","title":{"rendered":"Bliss GVS Pharma Share Price Target 2027: 19.3% Upside to Rs 781, Bull Case Rs 936"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Bliss GVS Pharma share price Rs 654.75 (10 November 2026). Base target Rs 781, bull Rs 936, downside risk Rs 521. PE 41.60. 52W range Rs 118.00 to Rs 739.90.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Bliss GVS Pharma share price target for 2027 is Rs 781, about 19.3% above the current price of Rs 654.75. The bull case is Rs 936, and the downside risk level, which is not a target, is Rs 521. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 29.9%, with the stock holding its PE of 41.60. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a Bliss GVS Pharma target price for 2027 should start with where the stock sits today. At Rs 654.75 on 10 November 2026, it is 11.5% below its 52-week high of Rs 739.90 and 454.9% above its 52-week low of Rs 118.00. That range spans 527% from low to high, so the entry point matters as much as the Bliss GVS Pharma price forecast itself.<\/p>\n<p>This article builds the Bliss GVS Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=bliss-gvs-pharma-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Bliss_GVS_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Bliss GVS Pharma Stock Analysis: Company Overview and Key Stats\">Bliss GVS Pharma Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Why_Is_Bliss_GVS_Pharma_Share_Price_Target_Set_at_Rs_781_for_2027\" title=\"Why Is Bliss GVS Pharma Share Price Target Set at Rs 781 for 2027?\">Why Is Bliss GVS Pharma Share Price Target Set at Rs 781 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Earnings_Growth_Behind_the_Bliss_GVS_Pharma_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Bliss GVS Pharma Target Price: Five Years of Results\">Earnings Growth Behind the Bliss GVS Pharma Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Valuation_Check_for_the_Bliss_GVS_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Bliss GVS Pharma Stock Target: PE, Price to Book and ROE\">Valuation Check for the Bliss GVS Pharma Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Bliss_GVS_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Bliss GVS Pharma Share Price Targets for the Short Term and 12 Months\">Bliss GVS Pharma Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Short_Term_Bliss_GVS_Pharma_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Bliss GVS Pharma Stock Target Levels: Technical Setup\">Short Term Bliss GVS Pharma Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#12_Month_Bliss_GVS_Pharma_Target_Price_for_2027\" title=\"12 Month Bliss GVS Pharma Target Price for 2027\">12 Month Bliss GVS Pharma Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Bliss_GVS_Pharma_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Bliss GVS Pharma Target Price\">How EPS Growth and PE Multiple Change the Bliss GVS Pharma Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Bliss_GVS_Pharma_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Bliss GVS Pharma Stock Target in 2027\">Bull Case and Downside Risk for Bliss GVS Pharma Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Bull_Case_Rs_936\" title=\"Bull Case Rs 936\">Bull Case Rs 936<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Downside_Risk_Level_Rs_521\" title=\"Downside Risk Level Rs 521\">Downside Risk Level Rs 521<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Key_Risks_to_the_Bliss_GVS_Pharma_Target_Price_for_2027\" title=\"Key Risks to the Bliss GVS Pharma Target Price for 2027\">Key Risks to the Bliss GVS Pharma Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Bliss_GVS_Pharma_Price_Target\" title=\"Growth Slowdown Risk for the Bliss GVS Pharma Price Target\">Growth Slowdown Risk for the Bliss GVS Pharma Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#How_to_Invest_in_Bliss_GVS_Pharma\" title=\"How to Invest in Bliss GVS Pharma\">How to Invest in Bliss GVS Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#FAQs_on_Bliss_GVS_Pharma_Share_Price_Target_2027\" title=\"FAQs on Bliss GVS Pharma Share Price Target 2027\">FAQs on Bliss GVS Pharma Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#What_is_the_Bliss_GVS_Pharma_share_price_target_for_2027\" title=\"What is the Bliss GVS Pharma share price target for 2027?\">What is the Bliss GVS Pharma share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#What_is_the_Bliss_GVS_Pharma_share_price_today\" title=\"What is the Bliss GVS Pharma share price today?\">What is the Bliss GVS Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Is_Bliss_GVS_Pharma_a_buy_or_sell_at_the_current_price\" title=\"Is Bliss GVS Pharma a buy or sell at the current price?\">Is Bliss GVS Pharma a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Bliss_GVS_Pharma_shares\" title=\"What are the bull case target and downside risk level for Bliss GVS Pharma shares?\">What are the bull case target and downside risk level for Bliss GVS Pharma shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#What_are_the_main_risks_to_the_Bliss_GVS_Pharma_price_target\" title=\"What are the main risks to the Bliss GVS Pharma price target?\">What are the main risks to the Bliss GVS Pharma price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#What_is_the_PE_ratio_of_Bliss_GVS_Pharma_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Bliss GVS Pharma and how does it compare with the industry?\">What is the PE ratio of Bliss GVS Pharma and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#Who_owns_Bliss_GVS_Pharma_and_what_is_the_promoter_holding\" title=\"Who owns Bliss GVS Pharma, and what is the promoter holding?\">Who owns Bliss GVS Pharma, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2027\/#What_were_Bliss_GVS_Pharmas_latest_quarterly_results\" title=\"What were Bliss GVS Pharma&#8217;s latest quarterly results?\">What were Bliss GVS Pharma&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Bliss GVS Pharma Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bliss GVS Pharma (NSE: BLISSGVS) has a market capitalisation of Rs 6,927 crore. In FY26 it reported revenue of Rs 1,001 crore and net profit of Rs 134.73 crore. The table collects the figures the Bliss GVS Pharma share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/blissgvs\/bliss-gvs-pharma-ltd-share-price-today\">Bliss GVS Pharma<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>BLISSGVS<\/td>\n<\/tr>\n<tr>\n<td>CMP (10 November 2026)<\/td>\n<td>Rs 654.75<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 739.90<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 118.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 6,927 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>41.60<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>40.13<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>5.37<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>12.49%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.02<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 15.65<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.15%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 781<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 936<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 521<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Bliss_GVS_Pharma_Share_Price_Target_Set_at_Rs_781_for_2027\"><\/span><strong>Why Is Bliss GVS Pharma Share Price Target Set at Rs 781 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 15.65 grown for one year gives a forward EPS estimate of Rs 18.78, and multiplying it by the unchanged PE of 41.60 gives the Rs 781 base-case Bliss GVS Pharma stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Bliss_GVS_Pharma_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Bliss GVS Pharma Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Bliss GVS Pharma grew revenue from Rs 778.95 crore in FY22 to Rs 1,001 crore in FY26, a compound annual growth rate of 6.5%. Net profit grew faster, from Rs 23.13 crore to Rs 134.73 crore (55.4% a year), which shows margin gains did part of the work and not just higher sales.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>778.95<\/td>\n<td>23.13<\/td>\n<td>1.43<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>769.37<\/td>\n<td>76.73<\/td>\n<td>6.72<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>798.98<\/td>\n<td>81.58<\/td>\n<td>7.11<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>846.22<\/td>\n<td>90.26<\/td>\n<td>7.95<\/td>\n<td>0.50<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>1,000.64<\/td>\n<td>134.73<\/td>\n<td>12.00<\/td>\n<td>0.50<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 18.2%, faster than the four-year average of 6.5%, and net profit moved up 49.3%. EPS rose from Rs 7.11 in FY24 to Rs 12.00 in FY26. The FY27 outlook for the Bliss GVS Pharma price target depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Bliss GVS Pharma converted 13.5% of FY26 revenue into net profit, against 10.7% in FY25, within a five-year range of 3.0% to 13.5%. EBITDA margin was 23.5% in FY26 versus 19.3% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 321.67 crore, up 27.2% from the same quarter a year earlier, while net profit of Rs 53.34 crore was up 86.6%. EBITDA came in at Rs 88.89 crore, up 71.2% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Bliss GVS Pharma stock target holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.02, and shareholders&#8217; equity grew from Rs 846.46 crore in FY22 to Rs 1,232 crore in FY26. Operating cash flow in FY26 was Rs 138.72 crore against capital expenditure of Rs 56.83 crore, leaving free cash flow of Rs 81.89 crore, or 1.2% of the current market capitalisation. In FY25 free cash flow was Rs 29.62 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Bliss_GVS_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Bliss GVS Pharma Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 41.60 against an industry PE of 40.13, Bliss GVS Pharma trades in line with its industry. Price to book is 5.37 on a book value of Rs 121.29 per share, and return on equity is 12.49%. A PE of 41.60 equals an earnings yield of 2.4%, and the FY26 dividend of Rs 0.50 per share gives a yield of 0.15%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 50.07% of Bliss GVS Pharma in September 2026, and promoter holding rose from 35.39% in September 2025 to 50.07% in September 2026. Foreign institutional investors (FII) held 5.03% and domestic institutions (DII) held 9.62%, which puts total institutional holding at 14.65%. FII holding fell from 13.27% in September 2025 to 5.03% in September 2026. Public shareholders own the remaining 35.28%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Bliss GVS Pharma Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Bliss_GVS_Pharma_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Bliss GVS Pharma Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 654.75 on 10 November 2026, Bliss GVS Pharma trades below its 50-day simple moving average of Rs 662.46 and above its 200-day exponential moving average of Rs 467.44. The 14-day RSI reads 57.7, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 662.46 (50-day simple moving average) and the nearest support is Rs 467.44 (200-day exponential moving average). A sustained move above Rs 662.46 would improve the short-term setup, while a close below Rs 467.44 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Bliss_GVS_Pharma_Target_Price_for_2027\"><\/span><strong>12 Month Bliss GVS Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target of Rs 781 means a move of 19.3% up from Rs 654.75 over the next 12 months. It would also push the stock above its 52-week high of Rs 739.90. Anyone checking the Bliss GVS Pharma share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Bliss_GVS_Pharma_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Bliss GVS Pharma Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 33.28<\/th>\n<th>PE 41.60<\/th>\n<th>PE 47.84<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 15.65)<\/td>\n<td>Rs 521<\/td>\n<td>Rs 651<\/td>\n<td>Rs 749<\/td>\n<\/tr>\n<tr>\n<td>20.0% (EPS Rs 18.78)<\/td>\n<td>Rs 625<\/td>\n<td>Rs 781<\/td>\n<td>Rs 898<\/td>\n<\/tr>\n<tr>\n<td>25.0% (EPS Rs 19.56)<\/td>\n<td>Rs 651<\/td>\n<td>Rs 814<\/td>\n<td>Rs 936<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Bliss GVS Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Bliss_GVS_Pharma_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Bliss GVS Pharma Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_936\"><\/span><strong>Bull Case Rs 936<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Bliss GVS Pharma price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 19.56, and a PE multiple that rises 15% to 47.84. That gives Rs 936, 43.0% above the current price and above the 52-week high of Rs 739.90, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_521\"><\/span><strong>Downside Risk Level Rs 521<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 15.65 and the PE falls 20% to 33.28. That gives Rs 521, 20.4% below the current price and above the 52-week low of Rs 118.00.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>25.0%<\/td>\n<td>47.84<\/td>\n<td>Rs 936<\/td>\n<td>+43.0%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>20.0%<\/td>\n<td>41.60<\/td>\n<td>Rs 781<\/td>\n<td>+19.3%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>33.28<\/td>\n<td>Rs 521<\/td>\n<td>-20.4%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Bliss_GVS_Pharma_Target_Price_for_2027\"><\/span><strong>Key Risks to the Bliss GVS Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Bliss_GVS_Pharma_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Bliss GVS Pharma Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 27.2% year on year, and FY26 revenue growth was 18.2%. If growth slows from here, the EPS estimate behind the Bliss GVS Pharma stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Bliss GVS Pharma has a market capitalisation of Rs 6,927 crore. Institutional holding is 14.65%, and promoters hold 50.07%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 13.5% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 41.60 versus an industry PE of 40.13, a de-rating toward the downside-risk PE of 33.28 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 57.7 and the MACD sits below its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Bliss_GVS_Pharma\"><\/span><strong>How to Invest in Bliss GVS Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Bliss GVS Pharma share price target is only as current as the data behind it, and the data here is as of 10 November 2026, so refresh the Rs 654.75 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Bliss GVS Pharma&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Bliss GVS Pharma fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Bliss GVS Pharma target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Bliss GVS Pharma live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Bliss GVS Pharma share price target for 2027 is Rs 781 in the base case, with Rs 936 as the bull case. The support for that view is arithmetic you can check: EPS grew 29.9% a year over FY24 to FY26, and the stock trades at a PE of 41.60. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the Bliss GVS Pharma price target, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Bliss_GVS_Pharma_Share_Price_Target_2027\"><\/span><strong>FAQs on Bliss GVS Pharma Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bliss_GVS_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Bliss GVS Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Bliss GVS Pharma share price target for 2027 is Rs 781, which is 19.3% above the price of Rs 654.75 on 10 November 2026. The bull case is Rs 936 and the downside risk level, which is not a target, is Rs 521. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bliss_GVS_Pharma_share_price_today\"><\/span><strong>What is the Bliss GVS Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 10 November 2026, 9:32 AM IST, Bliss GVS Pharma (NSE: BLISSGVS) trades at Rs 654.75, up 4.89% on the day. That is 11.5% below the 52-week high of Rs 739.90 and 454.9% above the 52-week low of Rs 118.00. The market capitalisation of Rs 6,927 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Bliss_GVS_Pharma_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Bliss GVS Pharma a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 29.9% a year over FY24 to FY26 and the base case implies 19.3% upside; on the cautious side, the stock sits 11.5% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 521 is 20% below the current price. Whether Bliss GVS Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Bliss_GVS_Pharma_shares\"><\/span><strong>What are the bull case target and downside risk level for Bliss GVS Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Bliss GVS Pharma share price target for 2027 is Rs 936, which assumes 25.0% EPS growth and a PE of 47.84, a 15% re-rating from today&#8217;s multiple. That is 43.0% above the current price and above the 52-week high of Rs 739.90, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 521, which assumes flat EPS and a PE of 33.28, 20% lower than today. It sits 20.4% below the current price and above the 52-week low of Rs 118.00, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Bliss_GVS_Pharma_price_target\"><\/span><strong>What are the main risks to the Bliss GVS Pharma price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Bliss GVS Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 6,927 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 33.28 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Bliss_GVS_Pharma_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Bliss GVS Pharma and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Bliss GVS Pharma is 41.60, against an industry PE of 40.13, which is a level close to the industry. Price to book is 5.37 and return on equity is 12.49%, and the PE equals an earnings yield of 2.4%. The base case holds the PE unchanged, so the Bliss GVS Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Bliss_GVS_Pharma_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Bliss GVS Pharma, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 50.07% of Bliss GVS Pharma in September 2026. FII held 5.03%, DII held 9.62% and the public held 35.28%. Together the two institutional groups hold 14.65%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Bliss_GVS_Pharmas_latest_quarterly_results\"><\/span><strong>What were Bliss GVS Pharma&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Bliss GVS Pharma reported revenue of Rs 321.67 crore (up 27.2% year on year) and net profit of Rs 53.34 crore (up 86.6%). For comparison, FY26 full-year revenue growth was 18.2% and net profit moved up 49.3%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Bliss GVS Pharma share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Bliss GVS Pharma share price target for 2027 is Rs 781, which is 19.3% above the price of Rs 654.75 on 10 November 2026. The bull case is Rs 936 and the downside risk level, which is not a target, is Rs 521. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Bliss GVS Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 10 November 2026, 9:32 AM IST, Bliss GVS Pharma (NSE: BLISSGVS) trades at Rs 654.75, up 4.89% on the day. That is 11.5% below the 52-week high of Rs 739.90 and 454.9% above the 52-week low of Rs 118.00. The market capitalisation of Rs 6,927 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Bliss GVS Pharma a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 29.9% a year over FY24 to FY26 and the base case implies 19.3% upside; on the cautious side, the stock sits 11.5% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 521 is 20% below the current price. Whether Bliss GVS Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Bliss GVS Pharma shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Bliss GVS Pharma share price target for 2027 is Rs 936, which assumes 25.0% EPS growth and a PE of 47.84, a 15% re-rating from today's multiple. That is 43.0% above the current price and above the 52-week high of Rs 739.90, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 521, which assumes flat EPS and a PE of 33.28, 20% lower than today. It sits 20.4% below the current price and above the 52-week low of Rs 118.00, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Bliss GVS Pharma price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Bliss GVS Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 6,927 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 33.28 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Bliss GVS Pharma and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Bliss GVS Pharma is 41.60, against an industry PE of 40.13, which is a level close to the industry. Price to book is 5.37 and return on equity is 12.49%, and the PE equals an earnings yield of 2.4%. The base case holds the PE unchanged, so the Bliss GVS Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Bliss GVS Pharma, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 50.07% of Bliss GVS Pharma in September 2026. FII held 5.03%, DII held 9.62% and the public held 35.28%. Together the two institutional groups hold 14.65%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Bliss GVS Pharma's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Bliss GVS Pharma reported revenue of Rs 321.67 crore (up 27.2% year on year) and net profit of Rs 53.34 crore (up 86.6%). For comparison, FY26 full-year revenue growth was 18.2% and net profit moved up 49.3%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bliss GVS Pharma share price target 2027: base Rs 781, bull Rs 936, downside risk level Rs 521, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":38,"featured_media":342714,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-342715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["342714"],"rank_math_title":["Bliss GVS Pharma Share Price Target 2027: 19.3% Upside and Risks"],"rank_math_description":["The Bliss GVS Pharma share price target for 2027 is Rs 781 against a price of Rs 654.75. Bull case, downside risk, earnings trend and risks explained. November 2026."],"rank_math_focus_keyword":["Bliss GVS Pharma share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/bliss-gvs-pharma-share-price-target-2027-19-3-upside-to-rs-781-bull-case-rs-936.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=342715"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342715\/revisions"}],"predecessor-version":[{"id":342716,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342715\/revisions\/342716"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/342714"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=342715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=342715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=342715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}